Pharvaris NV (FRA:9EN) Short Interest


FRA:9EN Pharvaris NV FRA:9EN
28 GF Score
Price €30.70
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:9EN vs BHVN, NRIX, VCEL: Short Interest Comparison

For the Biotechnology subindustry, Pharvaris NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Short Interest distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Short Interest falls into.


FRA:9EN
28GF Score
Pharvaris NV FRA:9EN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Business Description

Other Exchanges PHVS:USA
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
28GF Score

Get the complete analysis for FRA:9EN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.70
Price